Inactive

Domestic Industrial Base Expansion in Support of the National Response to the COVID-19 and/or Future Pandemics PURPOSE/DESCRIPTION Amendment 0001: The purpose of the amendment is to include additional... Domestic Industrial Base Expansion in Support of the National Response to the COVID-19 and/or Future Pandemics PURPOSE/DESCRIPTION Amendment 0001: The purpose of the amendment is to include additional language in the RFI and extend the proposal response date. The Department of Health and Human Services (HHS), in collaboration with the Air Force’s Acquisition COVID-19 Task Force (DAF ACT), is conducting a Request for Information (RFI) for information and planning purposes with the below priority access pre-requisite for initiatives executed under the American Rescue Plan Act of 2021: By entering into this contract, the contractor agrees to be legally bound to provide priority access for a 10-year period, starting from the date of contract award, notwithstanding the conclusion of any other contractual commitments at the end of this contract’s period of performance. “Priority access” is defined, for the purposes of this contract as: “PRIORITY ACCESS: Means that the U. S. Government has priority access to [FILL IN DESCRIPTION & CAPACITIES THAT THE U.S. GOVT. WILL RECEIVE PRIORITY ACCESS TO] over performance under any other contract or order, and, for the purpose of assuring such priority, shall be required to accept and perform such contracts or orders in preference to any other contracts during this 10 year period.” If the contractor novates or otherwise transfers responsibility for performance under this contract and commitments herein to any other entity, the priority access requirement shall follow the transfer and be the transferee will be legally bound to provide the priority access for the full 10-year period. The intent of this RFI is to understand Industry’s ability and willingness to provide the priority access as described and within the defined period. The COVID-19 pandemic caused a critical shortage of personnel protective equipment, pharmaceuticals, screening and diagnostics, and other medical domestic supply chain areas within our medical community. The current domestic Industrial Base Expansion efforts are designed to ensure that these critical shortages do not occur going forward. As the U.S. expands production, the U.S. Government (USG) would like to understand Industry’s ability to provide “priority access” in these areas so domestic access remains viable and accessible within the U.S. This language will apply to all areas of interest and mission areas that include but are not limited to: PPE (e.g. masks/fiber/materials/gloves/gowns) Screening & Diagnostics (e.g. rapid testing) Pharmaceuticals Vaccines Logistics (e.g. supply chain, raw materials, etc.) Medical (e.g. telehealth, medical capacity and sustainment, medical supplies and equipment, etc.) OTHER- Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic or future pandemics. CAUTION: This market survey is being conducted to understand Industry’s ability and willingness to provide the priority access as described and within the defined period to the domestic industrial base. The level of security clearance and amount of foreign participation in this requirement has not been determined. Contractors/Institutions responding to this market research are placed on notice that participation in this survey may not ensure participation in future solicitations or contract awards. The Government will not reimburse participants for any expenses associated with their participation in this survey. INSTRUCTIONS: The document below contains the legal definition of priority access and the defined period as well as a Contractor Capability Survey. The Survey allows Contractors to provide their company’s responses. Both large and small businesses are encouraged to participate in this Market Research. Joint ventures or teaming arrangements are encouraged. Interested parties shall respond to this RFI in a White Paper that is in a Microsoft Word for Office 2000 compatible format. Reponses to Part II of the Vendor Survey shall be limited to two (2) pages and submitted to the PCO via email only. Any proprietary information shall be clearly marked and segregated. Responses are due no later than 3:00 PM EDT on 6 October 2021. Questions relative to this market survey should be addressed to the PCO, Mrs. April Davison at april.davison.dafact@afwerx.af.mil. CONTRACTOR CAPABILITY SURVEY Part I. Business Information Please provide the following business information for your company/institution and for any teaming or joint venture partners: · Company/Institute Name: · Address: · Point of Contact: · CAGE Code: Phone Number: E-mail Address: Web Page URL: Your Industry: personnel protective equipment, pharmaceuticals, screening and diagnostics, or other medical domestic supply chain Based on the Government proposed NAICS Code, state whether your company is: Small Business (Yes / No) Woman Owned Small Business (Yes / No) Small Disadvantaged Business (Yes / No) 8(a) Certified (Yes / No) HUBZone Certified (Yes / No) Veteran Owned Small Business (Yes / No) Service Disabled Veteran Small Business (Yes / No) System for Award Management (SAM) (Yes / No) A statement as to whether your company is domestically or foreign owned (if foreign, please indicate the country of ownership). Responses to the Capability Survey Part I and Part II must be received no later than 3:00 PM EDT on 6 October 2021. Please ensure data is in a readable electronic format that can be received through a firewall. Attachments shall not to exceed 10 MB per email. Multiple emails are acceptable. Responses must be sent via email to the PCO, April Davison at april.davison.dafact@afwerx.af.mil. Questions relative to this market research should be addressed to the PCO. Part II. Capability Survey Questions Please address questions as they relate to the “Priority Access” language indicated below: By entering into this contract, the contractor agrees to be legally bound to provide priority access for a 10-year period, starting from the date of contract award, notwithstanding the conclusion of any other contractual commitments at the end of this contract’s period of performance. “Priority access” is defined, for the purposes of this contract as: “PRIORITY ACCESS: Means that the U. S. Government has priority access to [FILL IN DESCRIPTION & CAPACITIES THAT THE U.S. GOVT. WILL RECEIVE PRIORITY ACCESS TO] over performance under any other contract or order, and, for the purpose of assuring such priority, shall be required to accept and perform such contracts or orders in preference to any other contracts during this 10 year period.” If the contractor novates or otherwise transfers responsibility for performance under this contract and commitments herein to any other entity, the priority access requirement shall follow the transfer and be the transferee will be legally bound to provide the priority access for the full 10-year period. Are there any restraints cohering to the priority access language stated above? Please be specific with your response. Would the priority access language affect overall cost? If so, how? Please explain. If cost is affected by the priority access, is there a way to mitigate that cost, or substantially decrease the impact? Please explain. Is there any part of the priority access language that would affect your willingness to propose? What changes to the language would you require in order to submit a proposal?

Inactive

The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the Corona Virus Disease 2019 (COVID-19) pandemic. The Air Force Senior Acqu... The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the Corona Virus Disease 2019 (COVID-19) pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Defense Assisted Acquisition Cell, (DA2) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE’s): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort. As the U.S. Government response to the COVID-19 pandemic has evolved, the DA2 mission has also evolved to include the replenishment of the Strategic National Stockpile (SNS) and expand the domestic manufacture of key medical personnel protective equipment (PPE) items, screening and diagnostics instruments and supplies, finished drugs and active pharmaceutical ingredients and the associated finishing and delivery capabilities. The Department of the Air Force Acquisition Task Force (DAF ACT) combined with the DA2, will lead rapid solicitation and execution of contracts in support of the DA2 mission. This CSO announcement functions as the overarching umbrella solicitation from which the Team anticipates soliciting solution briefs through separate & periodically published Areas of Interest (AOI) to meet Department of Health and Human Services (HHS) COVID-19 response priorities; with an emphasis on SNS goals that achieve (i) more coverage to ensure sufficient inventory the major PPE, equipment and drugs associated with COVID-like pandemics, (ii) greater insight to forecast requirements, (iii) use various inventory management strategies and improved visibility into supply and demand, and (iv) enhance manufacturing capacity to reduce dependency on foreign sources of supply. Example description for known potential AoIs are called out in ATTACHMENT II. The CSO is a streamlined acquisition process that seeks to reduce acquisition timelines and acquire new, innovative solutions that companies can bring forth to meet the stated AoIs detailed in each Call. All details of the process shall be governed by this CSO unless otherwise noted or expanded upon in each AoI. Complete CSO details are contained in the attached document "DAF ACT Commercial Solutions Opening (CSO) COVID-19 Response" below. Interested parties should continue to monitor this Notice for updated information and publication of specific AoIs. UPDATED 12 NOV 2020: CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing, Closing 01 Dec 2020 UPDATED 12 NOV 2020: Correction of links at AoI-0001 - Rapid Point of Care Testing document paragraphs 3.0 and 4.0 UPDATED 13 NOV 2020: Add: ****Note to Vendor**** There is a technical issue with the links inside the attached PDFs. The 'Click' feature may not work. Please copy the link you desire and paste it into your browser Administrative update to CSO description and document; posted Revision 01 Publish AoI-0002 - Glove Industrial Base Expansion, Closing 30 Nov 2020 UPDATED 17 NOV 2020: Administrative update to CSO document to correct Contracting/Agreements Officer email addresses; posted Revision 02 Extended AoI-0001 Glove Industrial Base Expansion to 4:00 PM CST, 1 Dec 2020, posted Revision UPDATED 20 NOV 2020: Post Questions and Answers document dated 20 Nov 2020. UPDATED 30 NOV 2020: CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 01, Closing 01 Dec 2020 Extended AoI-0001 Rapid Point of Care Testing to 4:00 PM EST, 1 Dec 2020, posted Revision UPDATED 4 DEC 2020 CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 02, Closing 07 Dec 2020 Extended AoI-0001 Rapid Point of Care Testing to 4:30 PM CST, 7 Dec 2020, posted Revision UPDATED 4 DEC 2020 CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 03, Closing 07 Dec 2020 Extended AoI-0001 Rapid Point of Care Testing from 4:35 PM CST to 11:59 PM CST, 7 Dec 2020, posted Revision UPDATED 25 JAN 2021 CSO FA8119-21-S-C001 is hereby revised to extend the viability of the CSO only to 31 March 2021, and to update primary POCs. This revision to the CSO does not contain any new requests to vendors and thereby does not require any responses. In the event an additional AoI is let, this CSO will be revised accordingly. UPDATED 3 FEB 2021 CSO FA8119-21-S-C001 is hereby revised to correct the secondary Point of Contact (POC) name and email address. Secondary POC is Tisha McLelland, tisha.mclelland.dafact@afwerx.af.mil UPDATED 5 FEB 2021 CSO FA8119-21-S-C001 is updated by amendment to publish AoI-0003 - Supply Chain COVID-19 Diagnostic Testing, Closing 4:00 PM CST, 07 March 2021. UPDATED 11 FEB 2021 CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0003 – Supply Chain COVID-19 Diagnostic Testing Rev 01 The revision to the CSO makes clarifications to sections 2.0 and 3.1 of the AoI. UPDATED 7 MAR 2021 CSO FA8119-21-S-C001 is updated as follows: Extend AoI-0003 - Supply Chain COVID-19 Diagnostic Testing to 4PM CST, 8 March 2021 Update and replace attachment AoI 0003 - Supply Chain COVID-19 Diagnostic Testing to reflect revision 02 Update and replace CSO document labeled "DAF ACT Commercial Solutions Offering (CSO) COVID-19 Response Rev02". This document is updated to show the correct CSO close date of 31 March 2021 and remove Ms. Helaina Germosen as a point of contact.